EGFR and non-small cell lung carcinoma: The curve demonstrates that Model 5 consistently offers a superior net clinical benefit, especially across probability thresholds relevant to clinical decision making, reinforcing its applicability as a supportive tool for identifying NSCLC patients with a high likelihood of harboring EGFR mutations.